Dosing
Choose once-daily dosing or 3 times weekly dosing
*To be administered not more often than every other day.
- In both dosing regimens (QD and TIW), 91% of patients achieved two consecutive >30% iPTH reductions from baseline
- Dosing must be individualized and based on serum or plasma iPTH levels, with monitoring of serum calcium and serum phosphorus
- The adjacent tables are suggested approaches in titration
- Please see full prescribing information for additional dosing information
Zemplar Capsules are available in 3 strengths for
multiple dosing options
- No dosing adjustment is required in patients with mild or moderate hepatic impairment
- No overall differences in safety and effectiveness were observed between patients older and younger than 65 years
Monitoring instructions
- During the initial dosing or following any dose adjustment of medication, serum calcium, serum phosphorus, and serum or plasma PTH should be monitored at least every 2 weeks for 3 months, then monthly for 3 months, and every 3 months thereafter
- In clinical trials, if serum calcium was between 10.4 to 11.0 mg/dL, the dose was reduced irrespective of iPTH, and the dose was withheld if serum calcium was >11.0 mg/dL
- PTH and serum calcium levels should be monitored closely and dose adjustments of Zemplar may be required if a patient initiates or discontinues therapy with any strong CYP3A4 inhibitor, such as ketoconazole.
No special diet instructions required
- Zemplar Capsules can be taken with or without food
Multiple dosing options allow for individualized treatment of SHPT
